Pathogenesis of HIV-associated heart disease.
As longevity increases in HIV-infected individuals after the introduction of highly active antiretroviral therapy regimens, long-term effects such as cardiovascular disease and, more specifically, symptomatic heart failure are emerging as leading health issues. In the present review article, we discuss HIV-associated cardiovascular disease, focusing on etiopathogenetic mechanisms that may play a role in diagnosis, management, and therapy of HIV-associated heart failure in the highly active antiretroviral therapy era.
Barbaro
Giuseppe
G
Department of Medical Pathophysiology, University La Sapienza, Rome, Italy. g.barbaro@tin.it
D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D002311:Cardiomyopathy, Dilated / Q000821:virology; D002318:Cardiovascular Diseases / Q000821:virology*; D003327:Coronary Disease / Q000821:virology; D004730:Endothelium, Vascular; D015658:HIV Infections / Q000150:complications*; D006338:Heart Neoplasms / Q000821:virology; D006801:Humans; D006973:Hypertension / Q000821:virology; D009748:Nutrition Disorders / Q000821:virology; D010490:Pericardial Effusion / Q000821:virology; D018497:Ventricular Dysfunction, Right / Q000821:virology